Advertisement

Topics

Latest "Amphivena Therapeutics" News Stories - Page: 4

13:28 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Amphivena Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Amphivena Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Amphivena Therapeutics for you to read. Along with our medical data and news we also list Amphivena Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Amphivena Therapeutics Companies for you to search.

Showing "Amphivena Therapeutics" News Articles 76–100 of 7,900+

Probably Relevant

TG Therapeutics gets DSMB approval to continue two oncology trials

TG Therapeutics has secured a positive recommendation from the independent Data Safety Monitoring Boards (DSMBs) that evaluated data from the UNITY-CLL...Read More... The post TG Therapeutics gets DSMB approval to continue two oncology trials appeared first on Drug Development Technology.


Cybrexa Therapeutics Announces Multiple Oral Presentations Highlighting the Advances in the Application of DNA Repair Pathways in Cancer Drug Development at the DNA Damage Response Therapeutics Summit 2019

NEW HAVEN, Conn., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor-targeting platform, today announced that Dr. Vishwas Paralkar, Chief Scientific Officer of Cybrexa, and Dr. Ranjit Bindra, Cybrexa Scientific Co-founder and Associate Professor at the Yale School of Medicine, will deliver p...

New class of antisense oligonucleotide therapeutics tested in humans

A first-in-human study with a new class of antisense oligonucleotide therapeutics showed the ability to target the RNA-silencing drug to the liver, resulting in improved potency and safety at therapeutic doses. The design and results of this trial, conducted in healthy human volunteers are reported in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.


Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics publishes prospectus in connection with the list change to Nasdaq Stockholm

On August 30, 2018, Infant Bacterial Therapeutics AB (publ) ("IBT" or the "Company") announced that Nasdaq Stockholm's Listing Committee had approved the admission of the Company's shares of series...

Amicus Therapeutics to buy Celenex for $100m upfront

US-based biotechnology firm Amicus Therapeutics has entered into a definitive agreement to buy clinical stage gene therapy firm Celenex for...Read More... The post Amicus Therapeutics to buy Celenex for $100m upfront appeared first on Pharmaceutical Technology.

e-Therapeutics (ETX) - Releasing hidden value

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics (ETX) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson’s disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD’s platform. This has...

Finch Therapeutics’ C. Difficile infection drug gets breakthrough status

Microbial therapies developer Finch Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its...Read More... The post Finch Therapeutics’ C. Difficile infection drug gets breakthrough status appeared first on Pharmaceutical Technology.

Roche to Acquire Gene Therapy Firm Spark Therapeutics for $4.3 Billion

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) today announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. This corresponds to a total transaction value of approximately US$ 4.3 billion on …

e-Therapeutics (ETX) - The benefits of partnerships and cost control

Edison Investment Research - Pharmaceuticals & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing and non-dilutive financing. The FY19 operating loss was £5.1m, which is the same as our estimate. The cash outflow was £3.7m, resulting in a cash balance of £5.9m at the end of FY19. ...

Seelos Therapeutics Announces Successful Completion of its Merger with Apricus Biosciences

Seelos Therapeutics (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders, announced today the completion of its previously disclosed merger with Apricus Biosciences. As quoted in the press release: The combined company changed ...

STAT Plus: SQZ Therapeutics pushes forward with its method to squeeze drugs into cells

SQZ Therapeutics is working on a new way to get medicines into cells — and it's had a very busy fall.

This Day That Year: BioXcel Therapeutics

Shares of BioXcel Therapeutics Inc. (BTAI) are down nearly 47% from their all-time high of $14.79 recorded on July 10, 2018.

This Day That Year : Menlo Therapeutics

Shares of Menlo Therapeutics Inc. (MNLO) are down 86% from their 52-week high of $39.86 recorded on February 6, 2018.

Avenue Therapeutics, Inc. (ATXI) InvaGen Announces Acquisition Agreement with Avenue Therapeutics Conference Call (Transcript)

Smith & Nephew agrees to buy Osiris Therapeutics for $660m

Based in Columbia of Maryland, Osiris Therapeutics is engaged in the development, manufacturing and commercialization of regenerative medicine products such as skin, bone graft and articular cartilage substitutes. The post Smith & Nephew agrees to buy Osiris Therapeutics for $660m appeared first on Compelo Medical Devices - Latest industry news and analysis.

Deals this week: Biohaven Therapeutics, POXEL, Ossianix

Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....Read More... The post Deals this week: Biohaven Therapeutics, POXEL, Ossianix appeared first on Drug Development Technology.

5 Top Weekly NASDAQ Biotech Stocks: Magenta Therapeutics Rises

Magenta Therapeutics, China SXT Pharmaceuticals, Genocea Biosciences, MeiraGTx Holdings and Equillium were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Magenta Therapeutics Rises appeared first on Investing News Network.

FDA clears Fate Therapeutics’ stem cell therapy for an IND application

Fate Therapeutics has announced the US Food and Drug Administration (FDA) has allowed it to begin clinical investigation and submit...Read More... The post FDA clears Fate Therapeutics’ stem cell therapy for an IND application appeared first on Pharmaceutical Technology.

Why Pluristem Therapeutics believe that in cell therapy “the process is the product”

Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics

Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences

CRISPR Therapeutics will develop novel immune-oncology therapies after entering an agreement to use MaxCyte’s cell engineering platform. The partnership is an...Read More... The post Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences appeared first on Drug Development Technology.

United Therapeutics to Co-Develop MannKind's Dry Powder Treprostinil for PAH

United Therapeutics has agreed to license and co-develop MannKind’s clinical-phase dry powder formulation of the pulmonary arterial hypertension (PAH) treatment treprostinil—the active ingredient in United Therapeutics’ top-selling drugs Remodulin® and Tyvaso®—through a collaboration that could generate more than $95 million for MannKind, the companies said today. Under their...

Deals this week: Voyager Therapeutics, Pulmatrix, Horizon Discovery

Voyager Therapeutics will develop and commercialise Neurocrine Biosciences’ gene therapy candidates used to treat severe neurological conditions after a collaboration was...Read More... The post Deals this week: Voyager Therapeutics, Pulmatrix, Horizon Discovery appeared first on Drug Development Technology.

5 Top Weekly NASDAQ Biotech Stocks: Index Up During JPM Week

Axsome Therapeutics, Checkpoint Therapeutics, Bellerophon Therapeutics, Enochian Bioscience and Equillium were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Index Up During JPM Week appeared first on Investing News Network.

Roche kauft US-Biotechfirma für 4,3 Milliarden Dollar: Das Unternehmen Spark Therapeutics hat sich mit ...

Das Unternehmen Spark Therapeutics hat sich mit einer Gentherapie gegen Hämophilie hervorgetan. Nun greift Pharmariese Roche nach dem Expertenwissen und kauft Spark Therapeutics für eine Milliarden...

MannKind and United Therapeutics to advance dry powder treprostinil

US-based biopharmaceutical company MannKind has entered an exclusive licensing and collaboration agreement with United Therapeutics over a dry powder formulation...Read More... The post MannKind and United Therapeutics to advance dry powder treprostinil appeared first on Pharmaceutical Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks